AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04630119 — intervention group
Intervention type: OTHER
Intervention: Questionnaires on quality of life, emotional health and presenteeism
Description: After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
Study NCT00487240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
Study NCT00487240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Levemir
Description: Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
Study NCT02560961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (Kinesio Tex Gold®; color: black)
Description: Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
Study NCT02560961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Taping
Description: Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
Study NCT01221402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release niacin (Niaspan)
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
Study NCT01221402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: extended-release niacin (Niaspan)
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
Study NCT00240994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
Study NCT00240994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
Study NCT00240994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Per recommendation
Study NCT00240994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
Study NCT02353507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opticell Ag+
Study NCT02353507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag+
Study NCT03063021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC)
Description: Oral tablets of N-acetyl-cysteine
Study NCT04014127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
Study NCT04014127 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
Study NCT04014127 — intervention group
Intervention type: OTHER
Intervention: Urinary albumin/creatinine ratio
Description: Urine will be analysed for albumin/creatinine ratio
Study NCT01017640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02495493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction DCS chemotherapy
Description: docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
Study NCT00795288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin, 80 mg/day for 21 days
Description: Active treatment group
Study NCT01246310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol
Study NCT01246310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02596737 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: wittyFit concept
Study NCT01428583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone HCl and naltrexone HCl extended-release capsules
Description: Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Study NCT02370524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807
Description: All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
Study NCT01504997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted distal gastrectomy (DaVinci)
Description: patients who received robot assisted distal gastrectomy
Study NCT03473015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSO
Description: The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
Study NCT01799837 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [C-11]MENET
Description: PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
Study NCT02499484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate
Description: Topical GTN will be used daily in combination with a eccentric home exercise program
Study NCT02499484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Topical placebo ointment will be used in combination with a eccentric home exercise program
Study NCT02499484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise program
Description: All participants will complete the eccentric exercise program as a home exercise program daily.
Study NCT02499484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise program
Description: All participants will complete the eccentric exercise program as a home exercise program daily.
Study NCT03377257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolmitriptan by sublingual administration
Description: Experimental group
Study NCT02445404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
Study NCT03377257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolmitriptan by oral
Description: Active group
Study NCT00599053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 10 mg/kg IV per dose given for 10 days
Study NCT02445404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
Study NCT02445404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fractionated ICED
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
Study NCT02445404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fractionated ICED
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
Study NCT04037072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Topical application of Mytomycin C (MMC)
Study NCT03994822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy using the pRESET Thrombectomy device
Description: Clot removal using the pRESET Thrombectomy device
Study NCT03994822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Thrombectomy using the Solitaire Revascularization Device
Description: Clot removal using the Solitaire Revascularization Device
Study NCT00703872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral HDV-Interferon + ribavarin
Description: Naive pateints
Study NCT00703872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable HDV-Interferon + ribavarin
Description: Nonresponders
Study NCT03281759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial LED Therapy (Active coil helmet)
Description: The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
Study NCT03281759 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial LED Therapy (Inactive coil helmet)
Description: The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
Study NCT04477070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing with ultrasonic debridement
Description: Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
Study NCT04477070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional scaling and root planing
Description: Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
Study NCT01960335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
Study NCT01960335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
Study NCT01960335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein and Resistance Exericse
Description: Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
Study NCT01960335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein and RISE exercise routine
Description: Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
Study NCT04037072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Topical application of Normal Saline
Study NCT01765855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban single oral dose
Study NCT02584426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Distribution of Cefazolin
Study NCT01375790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise with Whole-body vibration platform
Description: The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
Study NCT01375790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
Study NCT02487680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids and chromium-picolinate containing drink
Description: Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
Study NCT02487680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Evaluation of the placebo supplement drink containing only aroma
Study NCT04045353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet education
Description: A 200 page informational document that connects with an online application will be provided to subjects.
Study NCT04045353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet education with behavioral component
Description: A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
Study NCT03278691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml saline IV Q6H
Study NCT03278691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15 mg (15 mg/ml) IV Q6H
Study NCT03149796 — intervention group
Intervention type: OTHER
Intervention: laboratory blood tests
Description: Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
Study NCT02068612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training+Interval Training
Study NCT02068612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Continuous Training
Study NCT02569918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation
Description: Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
Study NCT02033031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis intravitreal injection
Description: Lucentis intravitreal injection
Study NCT02033031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin intravitreal injection
Description: Avastin intravitreal injection
Study NCT02773602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 200 μgm/kg of dexamethasone in 1 ml saline
Study NCT02773602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 2 μg/kg of clonidine in 1 ml saline
Study NCT02773602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
Study NCT02203409 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic ALPPS
Description: Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
Study NCT04431765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization Reprocessing therapy
Description: The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
Study NCT04431765 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Trauma-Centred Cognitive and Behavioural Therapy
Description: A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
Study NCT01241110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin group A, Azitromycin group B
Description: Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
Study NCT01241110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azitromycin
Description: azitromicin vs ofluxacin
Study NCT00775619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol 12.5 mg tablets fed conditions
Study NCT00775619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol 12.5 mg tablets fed conditions
Study NCT03846193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT005
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
Study NCT03846193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GT005/ Device: Orbit™ Subretinal Delivery System
Description: A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel (Testosterone Gel)
Description: 1 mg tablet for 12 months
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Aromatase Inhibitor)
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Daily for 12 months
Study NCT00104572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Daily for 12 months
Study NCT04954963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reduce metal artifacts examination
Description: patients undergo reduce metal artifacts examination
Study NCT03285971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic CPP pager alert
Description: Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
Study NCT04173117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy meal replacement plan (12 weeks)
Description: Low energy meal replacement plan (12 weeks)
Study NCT04130282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313/Matrix-M1
Description: 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
Study NCT02815865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter and pitocin
Description: Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
Study NCT02815865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter and Dinoprostone
Description: Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
Study NCT02815865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone 3 mg will be inserted to the posterior fornix
Study NCT02973932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-bahavioral psychotherapy